Research programme: kinase-like protein 18A inhibitors - Satya Pharma
Alternative Names: Research programme: KIF18A inhibitors - Satya PharmaLatest Information Update: 05 Jan 2024
At a glance
- Originator Satya Pharma
- Class Antineoplastics; Small molecules
- Mechanism of Action KIF18A protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 11 Oct 2023 Preclinical trials in Cancer in India (PO) prior to October 2023
- 11 Oct 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC -2023)
- 27 Sep 2022 Early research in Cancer in India (PO), prior to September 2022 (Satya Pharma pipeline, September 2022)